{'fraction_non_alphanumeric': 0.016067329762815608, 'fraction_numerical': 0.011476664116296864, 'mean_word_length': 5.606060606060606, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Correction of anxiety depressive disorders with tianeptine in patients with heart failure in early period after myocardial infarction].

Aim of the study was clarification of the role of psychological characteristics of personality of patients, relationship between parameters of quality of life and clinical characteristics of the disease and their effect on peculiarities of the course of curative-rehabilitational process as well as clarification of spectrum of clinical activity and safety of tianeptine in anxiety-depressive states in patients with chronic heart failure in early post infarction period. Of 80 patients with anxiety-depressive disorders studied on days 15-30 after onset of disease, 30 received tianeptine (37.5 mg/day) for 3-6 months and 50 comprised control group. Significant reduction of symptoms of anxiety and depression and of cognitive-mnestic functions which occurred in tianeptine treated patients was accompanied with diminished severity of symptoms of heart failure and coronary insufficiency, lowering of index of local myocardial contractility and growth of ejection fraction. All of this resulted in improvement of quality of life of postinfarction patients, shortening of terms of rehabilitational period and allowed the patients to adapt better to surrounding reality.